It has been shown that strong SE‐CRC activity in certain types of cancer leads to “transcriptional addiction” and renders the cancer cells vulnerable to transcription‐targeted therapeutic strategies such as CDK7 inhibition.[24, 25, 26] Transcription inhibition preferentially suppresses the expression of master TFs and SE‐CRC activity, presenting a promising strategy to overcome key challenges of conventional drug therapies, including the lack of druggable targets and the emergence of drug resistance. This evidence concerns the gene CDK7 and cancer.